Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDH-013
- Development stage
- Unknown
- Lead developer
- MD Healthcare
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MDH-013 is an orally administered microbial extracellular vesicle (EV)-based therapeutic derived from *Lactobacillus paracasei* (LpEVs), developed by MD Healthcare in collaboration with Kolmar Korea. MDH-013 is designed to target the unfolded protein response (UPR) to alleviate endoplasmic reticulum (ER) stress, thereby suppressing inflammation and cell death. The therapeutic is currently in Phase 1 clinical development for the treatment of various solid cancers, including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), pancreatic cancer, hepatobiliary cancer, renal and bladder cancer, and breast and ovarian cancer. Additionally, MDH-013 has demonstrated preclinical efficacy in animal models of inflammatory bowel disease (IBD) by reducing dextran sulfate sodium (DSS)-induced colitis.
- Other names
- Lactobacillus paracasei-derived EVsLactobacillus paracasei-derived extracellular vesiclesLpEVs
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on MDH-013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDH-013.